Effects of Mild Hypoglycaemia on Cognitive Function in Type 2 Diabetes

Hypoglycemia Clinical Trial

Official title:

Effects of Mild Hypoglycaemia on Cognitive Function in Type 2 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03014011
• Other study ID #: MISP
• Status: Completed
• Phase: N/A
• Start date: June 13, 2017
• Est. completion date: July 24, 2018

Study information

• Verified date: December 2019
• Source: Bispebjerg Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Hypoglycaemia in subjects suffering from type 2 diabetes may have substantial consequences including a significant negative impact on quality of life. Further, repeated minor hypoglycaemias may result in significant productivity losses.

Here, the investigators propose to provide quantitative results on cognition during an acute mild hypoglycaemic episode (target plasma glucose 3 mmol/L) in 28 subjects with type 2 diabetes. Data will be provided on executive function, attention and memory.

Description:

Hypoglycaemia in subjects suffering from type 2 diabetes may have substantial consequences including a significant negative impact on quality of life. Further, repeated minor hypoglycaemias may result in significant productivity losses. In healthy subjects a number of studies show that during a hypoglycaemic episode with plasma levels of 2.2 - 2.5 mmol/L (40-45 mg/dl) brain areas responsible for cognition have an altered neuronal function when measuring cerebral blood flow. This is accompanied by severely impaired cognitive function with a reduced ability to solve simple cognitive tasks. At higher levels of glucose (above 3 mmol/L (54 mg/dl)), it remains to be settled whether cognitive functions are also affected negatively and whether this may be accompanied by changes in brain metabolism. Apart from raising the blood glucose directly or indirectly via glucagon, no treatment for hypoglycaemia exists, but since Glucagon-like peptide-1 (GLP-1) based therapies used in type 2 diabetes may affect brain glucose consumption, therapeutic interventions to prevent negative results of hypoglycaemia may eventually become clinically possible.

Here, the investigators propose to provide quantitative results on cognition during an acute mild hypoglycaemic episode (target plasma glucose 3 mmol/L). Data will be provided on executive function, attention and memory.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: July 24, 2018
• Est. primary completion date: July 23, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 35 Years to 70 Years

Eligibility

Inclusion Criteria:

• Informed and written consent

• Clinically diagnosed type 2 diabetes mellitus for at least 3 months (diagnosed according to the criteria of the World Health Organization (WHO)).

• Normal haemoglobin = 8.0 mmol/L (male) or = 6.4 mmol/L (female)

• Male or female participants aged 35-70 years, both inclusive.

• Treated with diet or any antidiabetic medication except sulfonylureas, meglitinides or insulin.

• HbA1c = 9.0 % by local laboratory analysis.

• BMI >23 kg/m2 and <35 kg/m2

Exclusion Criteria:

• Receipt of any investigational medicinal product within 3 months before screening in this trial.

• Liver disease (alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase (ASAT) >2 times normal values) or history of hepatobiliary disorder.

• Nephropathy (serum creatinine levels = 126 µmol/L (male) or = 111 µmol/L (female)).

• Cardiac problems defined as decompensated heart failure (New York Heart Association (NYHA) class III and IV) at any time and/or angina pectoris within the last 12 months and/or acute myocardial infarction at any time.

• Active or recent malignant disease.

• Treatment with drugs that cannot be paused for 12 hours.

• Repeated resting blood pressure at screening outside the range 90-140 mmHg for systolic or 50-90 mmHg for diastolic. This exclusion criterion also pertains to subjects taking antihypertensives.

• Visual impairment or auditory impairment.

• Known abnormalities of the central nervous system or any endocrinological (with the exception of diabetes mellitus and euthyroid goiter), haematological, neurological, psychiatric diseases or other major disorders that in the opinion of the investigator precludes compliance with the protocol, evaluation of the results or represent an unacceptable risk for the participant's safety.

• Proliferative retinopathy (funduscopy performed within 3 months before the screening is acceptable) and/or severe neuropathy.

• Current treatment with systemic drugs, which may interfere with glucose metabolism.

• Significant history of alcoholism or drug/chemical abuse as per investigator's judgement.

• Current tobacco user (smoking or nicotinic product use 3 months prior to screening).

• Severe hypoglycaemic event during the past 6 months.

• Known hypoglycaemia unawareness.

• Participants with mental incapacity or language barriers precluding adequate understanding or co-operation or who, in the opinion of the investigator or their general practitioner, should not participate in the trial.

• For females only: Pregnancy, breast-feeding status or intention of becoming pregnant during the trial.

• Any chronic disorder or severe disease that in the opinion of the investigator might endanger participant's safety or compliance with the protocol.

Related Conditions & MeSH terms

• Cognitive Change
• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Diabetes Mellitus, Type II
• Hypoglycemia

Intervention

Other:
• Hypoglycaemic clamp
The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to lower and keep plasma blood glucose levels at 3 mmol/L for outcome measurements.
• Euglycaemic clamp
The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to keep plasma blood glucose levels at 6 mmol/L for outcome measurements.

Locations

Country	Name	City	State
Denmark	Department of Research in Endocrinology, Bispebjerg University Hospital	Copenhagen

Sponsors (3)

Lead Sponsor	Collaborator
Bispebjerg Hospital	Psychiatric Centre Rigshospitalet, University Hospital, Gentofte, Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Psychomotor Speed	Symbol Digit Modalities Test was used as a measurement of psychomotor speed.; For the Symbol Digit Modalities Test, participants were required to use a coded key to match nine abstract symbols paired with numerical digits. The final score is the correct number of substitutions in 120 s, and scores range between 0 and 110. Higher values represent a better outcome.	All neurocognitive testing was assessed at each intervention when glucose levels had been stabile for 40 minutes, an average of 2 hours after clamp procedure start. The duration of neurocognitive testing was approximately 40 min.